We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a ne

Simply Wall StMay 8 20:47

Buy Rating on Oric Pharmaceuticals Amidst Strong Financials and Promising Clinical Pipeline

TipRanksMay 8 18:27

Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)

TipRanksMay 8 12:50

Oric Pharmaceuticals Price Target Cut to $14.00/Share From $15.00 by Citigroup

Oric Pharmaceuticals Price Target Cut to $14.00/Share From $15.00 by Citigroup

Dow JonesMay 8 01:47

Oric Pharmaceuticals Is Maintained at Buy by Citigroup

Oric Pharmaceuticals Is Maintained at Buy by Citigroup

Dow JonesMay 8 01:47

Citi: Maintains ORIC Pharmaceuticals (ORIC.US) rating, adjusted from buy to buy rating, and adjusted the target price from $15.00 to $14.00.

Citi: Maintains ORIC Pharmaceuticals (ORIC.US) rating, adjusted from buy to buy rating, and adjusted the target price from $15.00 to $14.00.

Zhitong FinanceMay 8 01:40